Literature DB >> 16314802

Effect of FTY720 on chronic cyclosporine nephropathy in rats.

Jin Young Kim1, Sun Woo Lim, Can Li, Jung Shim Kim, Kyung Ohk Ahn, Hyun Joo Yang, Bum Soon Choi, Yong Soo Kim, Jin Kim, Byung Kee Bang, Chul Woo Yang.   

Abstract

BACKGROUND: Long-term treatment with cyclosporine A (CsA) causes tubulointerstitial inflammation and fibrosis in the kidney. To define the role of lymphocytes in this process, the novel lymphocyte-specific inhibitor FTY720 was administered to rats with experimental model of chronic CsA nephropathy.
METHODS: Sprague-Dawley rats were treated daily for 4 weeks with CsA (7.5 mg/kg), or both CsA and FTY720 (0.125 mg/kg). The effects of FTY720 on CsA-induced renal injury were evaluated using renal function tests and histopathology, and the expression of mediators of CsA-induced renal injury (osteopontin, transforming growth factor-beta1 [TGF-beta1], betaig-h3, and angiotensin II).
RESULTS: FTY720 treatment significantly decreased T-lymphocyte accumulation in kidneys compared with CsA treatment alone. FTY720 treatment improved not only CsA-induced renal dysfunction but also renal histopathology, demonstrated by decreased macrophage infiltration and interstitial fibrosis. Increased osteopontin, TGF-beta1, betaig-h3, and angiotensin II expression in CsA-treated rat kidneys were decreased with FTY720 treatment.
CONCLUSIONS: FTY720 treatment prevents CsA-induced renal injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16314802     DOI: 10.1097/01.tp.0000189709.21474.33

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

Review 1.  Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease.

Authors:  S-K Jo; A Bajwa; A S Awad; K R Lynch; M D Okusa
Journal:  Kidney Int       Date:  2008-03-05       Impact factor: 10.612

Review 2.  The influence of sphingosine-1-phosphate receptor signaling on lymphocyte trafficking: how a bioactive lipid mediator grew up from an "immature" vascular maturation factor to a "mature" mediator of lymphocyte behavior and function.

Authors:  Michael D Davis; John H Kehrl
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

Review 3.  The pathogenesis and treatment of chronic allograft nephropathy.

Authors:  Can Li; Chul Woo Yang
Journal:  Nat Rev Nephrol       Date:  2009-07-28       Impact factor: 28.314

4.  Comparison of early and late conversion of sirolimus in experimental model of chronic cyclosporine nephropathy.

Authors:  Jin Young Kim; Jung Yeon Ghee; Sun Woo Lim; Shang Guo Piao; Byung Ha Chung; Hye Eun Yoon; Hyeon Seok Hwang; Bum Soon Choi; Jin Kim; Chul Woo Yang
Journal:  J Korean Med Sci       Date:  2012-01-27       Impact factor: 2.153

5.  Shen-Kang protects against tacrolimus-induced renal injury.

Authors:  Long Ye Zhang; Jian Jin; Kang Luo; Shang Guo Piao; Hai Lan Zheng; Ji Zhe Jin; Sun Woo Lim; Bum Soon Choi; Chul Woo Yang; Can Li
Journal:  Korean J Intern Med       Date:  2018-02-12       Impact factor: 2.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.